Brief: Regent Pacific Announces Submission Of Senstend New Drug Application To NMPA In China
18/12/2024 10:18
Dec 18 (Reuters) - Regent Pacific Group Ltd 0575.HK :
* SUBMISSION OF SENSTEND NEW DRUG APPLICATION TO NMPA IN
CHINA
Further company coverage: 0575.HK
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Regent Pacific
See all newsBrief: Regent Pacific Says SenstendTM Approved By NMPA For Premature Ejaculation In China
Brief: Regent Pacific Says Deep Longevity To Launch U.S. Expansion In Q1 2026
Brief: Regent Pacific Shall Allot And Issue 63.4 Million Shares At Hk$0.485 Per Share
Brief: Regent Pacific Announces Submission Of Senstend New Drug Application To NMPA In China
Brief: Regent Pacific Enters Manufacturing And Supply Agreement For SENSTEND